NCT03120624 - VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 15, 2017

Primary Completion Date

August 29, 2023

Study Completion Date

January 1, 2028

Conditions

Metastatic Endometrial CarcinomaRecurrent Endometrial AdenocarcinomaRecurrent Endometrial CarcinomaRecurrent Endometrial Clear Cell AdenocarcinomaRecurrent Endometrial Endometrioid AdenocarcinomaRecurrent Endometrial Mixed Cell AdenocarcinomaRecurrent Endometrial Serous AdenocarcinomaRecurrent Endometrial Undifferentiated CarcinomaRecurrent Uterine Corpus CarcinosarcomaStage IV Uterine Corpus Cancer AJCC v7

Interventions

PROCEDURE

Biopsy

Undergo image-guided biopsy

PROCEDURE

Computed Tomography

Undergo CT

OTHER

Fluorine F 18 Tetrafluoroborate

Given IV

OTHER

Pharmacological Study

Correlative studies

PROCEDURE

Positron Emission Tomography

Undergo TFB-PET

BIOLOGICAL

Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter

Given IV

DRUG

Ruxolitinib Phosphate

Given PO

DRUG

Technetium Tc-99m Sodium Pertechnetate

Given IV

PROCEDURE

Biospecimen Collection

Undergo mouth rinse, buccal swab, urine, and blood sample collection

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester